Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin effects on GFR and ambulatory blood pressure in adults with type 2 diabetes and inadequate glycemic and blood pressure control
NL-OMON33243Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Percent change from baseline in glomerular filtration rate, Change from baseline in mean ambulatory systolic blood pressure and 2 more. Started Jan 2010; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON33243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33243.